ClinicalTrials.gg
CompletedNCT01312961Updated Jun 8, 2017Results posted

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

A Phase 2 interventional study of Dupilumab and Placebo (for Dupilumab) in Asthma, sponsored by Sanofi. Completed at 50 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
19th of 31
104 · median 120
Started
2011
the only one that year
Phase 2
5 of 31
none open now
Registered
1st of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 19th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 2, and was the 1st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma.

Secondary Objectives:

  • To assess the safety and tolerability of Dupilumab administered SC qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
  • To assess Dupilumab serum concentrations following qw SC dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.
Read the detailed description

The total duration of the study period per participant was 20-22 weeks broken down as follows:

  • Screening period: up to 14 days,
  • Treatment period: 12 weeks,
  • Follow-up period: 6-8 weeks.
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Medical diagnosis of persistent asthma for at least 12 months whose:

  • airway inflammation likely to be eosinophilic,
  • asthma partially controlled or uncontrolled on ICS plus LABA therapy.
  • On a stable dose of either Fluticasone/Salmeterol, Budesonide/Formoterol, Mometasone/Formoterol combination therapy for at least 1 month prior to screening.
  • Signed an Form and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form.

Exclusion criteria

Exclusion criteria:

  • Less than 18 years or greater than 65 years of age.
  • abnormal laboratory values suggesting an unknown disease and requiring further evaluation.
  • and/or other lung diseases impairing Pulmonary Function Tests.
  • Beta-adrenergic receptor blockers required for any reason.
  • Current smoker or cessation of smoking within the 6 months prior to screening.
  • Previous smoking with a smoking history >10 cigarette pack/years.
  • Participation in another study within 6 months prior to screening if the study medication was an antibody or within 30 days prior to screening for all other study medications.
  • Known or suspected non-compliance, alcohol or drug abuse.
  • Inability to follow the procedures of the study (e.g, due to language problems, psychological disorders).
  • Concomitant severe diseases or diseases for which the use of ICS or LABA were .
  • Known allergy to doxycycline or related compounds.
  • Pregnancy or intention to become pregnant during the course of the study, breast feeding, or unwillingness to use a highly effective method of throughout the study in women of .
  • Recent history of a parasitic infection or travel to a parasitic endemic area within 6 months prior to screening.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Placebo comparator
    Placebo (for Dupilumab)

    Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.

    Drug: Placebo (for Dupilumab) · Drug: Fluticasone/Salmeterol combination therapy · Drug: Fluticasone monotherapy · Drug: Albuterol · Drug: Levalbuterol

  • Experimental
    Dupilumab 300 mg qw

    Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.

    Drug: Dupilumab · Drug: Fluticasone/Salmeterol combination therapy · Drug: Fluticasone monotherapy · Drug: Albuterol · Drug: Levalbuterol

Interventions

  • Solution for injection, one subcutaneous injection.

    Also known as: SAR231893, REGN668

  • DrugPlacebo (for Dupilumab)

    Solution for injection, one subcutaneous injection.

  • DrugFluticasone/Salmeterol combination therapy

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Oral inhalation twice daily.

  • Oral inhalation twice daily.

  • Oral inhalation as needed.

  • Oral inhalation as needed.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Asthma Exacerbation

    An asthma exacerbation was defined as the occurrence of any of the following: ≥30% reduction from baseline in morning PEF on 2 consecutive days; or ≥6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; or deterioration of asthma, as determined by the investigator, requiring systemic steroid treatment, or an increase in inhaled corticosteroid (ICS) of ≥4 times the last dose received prior to discontinuation from the study, or hospitalization. The occurrence of asthma exacerbations by individual criteria are reported.

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12

    The time-to-asthma exacerbation was defined as the time from the date of randomization to the date of the first asthma exacerbation event; for participants without asthma exacerbation, it was censored at the end of treatment visit date. The median time to first asthma exacerbation was not estimated because the number of asthma exacerbations was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of asthma exacerbation at Week 4, 8 and 12, are presented as the descriptive measure statistics.

    Time frame: Baseline up to Week 12

  2. Percentage of Participants With Composite Asthma Events

    Composite asthma event was defined as a 30% or greater reduction from baseline in morning PEF on 2 consecutive days together with 6 or more additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days.

    Time frame: Baseline up to Week 12

  3. Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Peak Expiratory Flow (PEF) to Week 12

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12

    ACQ-5 questionnaire is a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score is the mean of the 5 questions and range between 0 (disease totally controlled) and 6 (disease severely uncontrolled), a higher score indicated lower asthma control.

    Time frame: Baseline, Week 12

  6. Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12

    The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Morning Asthma Symptom Scores to Week 12

    AM (ante meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning. No nighttime awakenings,2= Woke up once because of asthma (including early awakening),3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.

    Time frame: Baseline, Week 12

  8. Change From Baseline in Evening Asthma Symptom Scores to Week 12

    PM (post meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the day. It ranges from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12

    Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.

    Time frame: Baseline, Week 12

  10. Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12

    Number of Albuterol or Levalbuterol inhalations were recorded daily by the participants in their electronic diary as Albuterol or Levalbuterol was to be used only as needed for symptoms, not on a regular basis or prophylactically.

    Time frame: Baseline, Week 12

07

Results

Posted Jun 8, 2017

Participant flow

The study was conducted at 50 sites in the United States. A total of 491 participants were screened between March 2011 and June 2012, of whom 104 were randomized at 28 sites. A total of 387 participants were screen failures mainly due to inclusion criteria for eosinophilic asthma not met.

Participant flow — Overall Study
MilestonePlacebo (for Dupilumab)Dupilumab 300 mg qw
Started5252
Treated5252
Completed3545
Not completed177
Withdrew: Adverse event33
Withdrew: Lack of efficacy111
Withdrew: Poor compliance to protocol10
Withdrew: Other than specified above23

Outcome measures

PrimaryPercentage of Participants With Asthma Exacerbation

An asthma exacerbation was defined as the occurrence of any of the following: ≥30% reduction from baseline in morning PEF on 2 consecutive days; or ≥6 additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; or deterioration of asthma, as determined by the investigator, requiring systemic steroid treatment, or an increase in inhaled corticosteroid (ICS) of ≥4 times the last dose received prior to discontinuation from the study, or hospitalization. The occurrence of asthma exacerbations by individual criteria are reported.

Time frame:
Baseline up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Asthma Exacerbation
percentage of participantsPlacebo (for Dupilumab)Dupilumab 300 mg qw
Asthma exacerbation44.25.8
≥30% reduction from baseline in morning PEF19.21.9
≥6additional albuterol/levalbuterol puffs19.21.9
Systemic steroid treatment9.61.9
Increase in ICS ≥4 times baseline dose of ICS5.80.0
Hospitalization0.00.0
Statistical analysis
  • Placebo (for Dupilumab) vs Dupilumab 300 mg qw · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 0.077 · 95% CI 0.021 to 0.280Dupilumab 300 mg vs. Placebo
SecondaryTime to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12

The time-to-asthma exacerbation was defined as the time from the date of randomization to the date of the first asthma exacerbation event; for participants without asthma exacerbation, it was censored at the end of treatment visit date. The median time to first asthma exacerbation was not estimated because the number of asthma exacerbations was too low in the Dupilumab arm. Therefore, alternative Kaplan-Meier statistics, the probability of asthma exacerbation at Week 4, 8 and 12, are presented as the descriptive measure statistics.

Time frame:
Baseline up to Week 12
Reported as:
Number · Probability of asthma exacerbation
Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12
Probability of asthma exacerbationPlacebo (for Dupilumab)Dupilumab 300 mg qw
Probability at Week 40.058 (0.000 to 0.122)0.038 (0.000 to 0.091)
Probability at Week 80.245 (0.124 to 0.366)0.058 (0.000 to 0.121)
Probability at Week 120.460 (0.318 to 0.602)0.058 (0.000 to 0.121)
SecondaryPercentage of Participants With Composite Asthma Events

Composite asthma event was defined as a 30% or greater reduction from baseline in morning PEF on 2 consecutive days together with 6 or more additional reliever puffs of albuterol or levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days.

Time frame:
Baseline up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Composite Asthma Events
percentage of participantsPlacebo (for Dupilumab)Dupilumab 300 mg qw
Percentage of Participants With Composite Asthma Events1.90
SecondaryChange From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.

Time frame:
Baseline, Week 12
Reported as:
Mean · Liters
Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12
LitersPlaceboDupilumab 300 mg qw
Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12-0.12 ± 0.350.06 ± 0.32
SecondaryChange From Baseline in Peak Expiratory Flow (PEF) to Week 12

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.

Time frame:
Baseline, Week 12
Reported as:
Mean · liters/minute
Change From Baseline in Peak Expiratory Flow (PEF) to Week 12
liters/minutePlacebo (for Dupilumab)Dupilumab 300 mg qw
Change in morning PEF-11.2 ± 66.110.6 ± 48.5
Change in evening PEF-15.6 ± 70.7-3.4 ± 49.3
SecondaryChange From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12

ACQ-5 questionnaire is a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score is the mean of the 5 questions and range between 0 (disease totally controlled) and 6 (disease severely uncontrolled), a higher score indicated lower asthma control.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12
units on a scalePlacebo (for Dupilumab)Dupilumab 300 mg qw
Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12-0.50 ± 1.12-1.07 ± 0.94
SecondaryChange From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12

The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12
units on a scalePlacebo (for Dupilumab)Dupilumab 300 mg qw
Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 121.27 ± 15.85-9.17 ± 15.40
SecondaryChange From Baseline in Morning Asthma Symptom Scores to Week 12

AM (ante meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the night. It ranges from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning. No nighttime awakenings,2= Woke up once because of asthma (including early awakening),3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Morning Asthma Symptom Scores to Week 12
units on a scalePlacebo (for Dupilumab)Dupilumab 300 mg qw
Change From Baseline in Morning Asthma Symptom Scores to Week 120.3 ± 0.7-0.4 ± 0.7
SecondaryChange From Baseline in Evening Asthma Symptom Scores to Week 12

PM (post meridiem) symptom scoring system rates were participant's overall asthma symptoms experienced during the day. It ranges from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Evening Asthma Symptom Scores to Week 12
units on a scalePlacebo (for Dupilumab)Dupilumab 300 mg qw
Change From Baseline in Evening Asthma Symptom Scores to Week 120.1 ± 0.9-0.5 ± 0.6
SecondaryChange From Baseline in Number of Nocturnal Awakenings Per Day to Week 12

Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.

Time frame:
Baseline, Week 12
Reported as:
Mean · number of awakenings/day
Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12
number of awakenings/dayPlacebo (for Dupilumab)Dupilumab 300 mg qw
Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 120.1 ± 0.7-0.3 ± 0.7
SecondaryChange From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12

Number of Albuterol or Levalbuterol inhalations were recorded daily by the participants in their electronic diary as Albuterol or Levalbuterol was to be used only as needed for symptoms, not on a regular basis or prophylactically.

Time frame:
Baseline, Week 12
Reported as:
Mean · number of inhalations/day
Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12
number of inhalations/dayPlacebo (for Dupilumab)Dupilumab 300 mg qw
Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 120.4 ± 2.4-1.3 ± 1.7

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (for Dupilumab)0/52 (0%)3/52 (5.8%)24/52 (46.2%)
Dupilumab 300 mg qw0/52 (0%)1/52 (1.9%)33/52 (63.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo (for Dupilumab)Dupilumab 300 mg qw
PneumoniaInfections and infestations1/520/52
Bipolar disorderPsychiatric disorders0/521/52
AsthmaRespiratory, thoracic and mediastinal disorders1/520/52
PneumothoraxRespiratory, thoracic and mediastinal disorders1/520/52
Ankle fractureInjury, poisoning and procedural complications1/520/52
Gun shot woundInjury, poisoning and procedural complications1/520/52
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo (for Dupilumab)Dupilumab 300 mg qw
Upper respiratory tract infectionInfections and infestations9/527/52
NasopharyngitisInfections and infestations2/527/52
HeadacheNervous system disorders3/526/52
SinusitisInfections and infestations5/521/52
Injection site painGeneral disorders3/525/52
Injection site reactionGeneral disorders0/525/52
NauseaGastrointestinal disorders1/524/52
Gastroenteritis viralInfections and infestations3/520/52
Viral upper respiratory tract infectionInfections and infestations0/523/52
Nasal congestionRespiratory, thoracic and mediastinal disorders1/523/52

Baseline characteristics

Baseline participants included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
Mean41.6 ± 13.137.8 ± 13.239.7 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
Female262652
Male262652
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
Hispanic or Latino41216
Not Hispanic or Latino484088
Unknown or Not Reported000
Race
Race(Participants)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
Caucasian/White384583
Black9514
Asian/Oriental314
Other than specified above213
Prior ICS/LABA Combination Therapy Dose
Prior ICS/LABA Combination Therapy Dose(Participants)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
High Dose414283
Medium Dose111021
Morning Peak Expiratory Flow (PEF)
Morning Peak Expiratory Flow (PEF)(L/min)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
Mean406.87 ± 110.74393.04 ± 101.13400.02 ± 105.80
Number of Inhalations of Albuterol or Levalbuterol in a 24-hour Period
Number of Inhalations of Albuterol or Levalbuterol in a 24-hour Period(number of inhalations)Placebo (for Dupilumab)Dupilumab 300 mg qwTotal
Mean2.04 ± 1.782.16 ± 2.402.10 ± 2.10
08

Study locations

50 sites
  • Investigational Site Number 840047
    Anaheim, California 92804, United States
  • Investigational Site Number 840046
    Long Beach, California 90806, United States
  • Investigational Site Number 840032
    Los Angeles, California 90025, United States
  • Investigational Site Number 840036
    Los Angeles, California 90048, United States
  • Investigational Site Number 840005
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840007
    Orange, California 92868, United States
  • Investigational Site Number 840048
    Riverside, California 92506, United States
  • Investigational Site Number 840035
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 840041
    San Francisco, California 94143, United States
  • Investigational Site Number 840042
    San Francisco, California 94143, United States
  • Investigational Site Number 840039
    San Jose, California 95117, United States
  • Investigational Site Number 840024
    Santa Rosa, California 95405, United States
  • Investigational Site Number 840002
    Stockton, California 95207, United States
  • Investigational Site Number 840031
    Colorado Springs, Colorado 80907, United States
  • Investigational Site Number 840011
    Denver, Colorado 80206, United States
  • Investigational Site Number 840017
    Denver, Colorado 80230, United States
  • Investigational Site Number 840026
    New Haven, Connecticut 06510, United States
  • Investigational Site Number 840044
    Tallahassee, Florida 32308, United States
  • Investigational Site Number 840029
    Tampa, Florida 33612, United States
  • Investigational Site Number 840028
    Indianapolis, Indiana 46208, United States
  • Investigational Site Number 840038
    Iowa City, Iowa 52240, United States
  • Investigational Site Number 840021
    Overland Park, Kansas 66210, United States
  • Investigational Site Number 840053
    Owensboro, Kentucky 42303, United States
  • Investigational Site Number 840014
    Baltimore, Maryland 21287, United States
  • Investigational Site Number 840015
    North Dartmouth, Massachusetts 02747, United States
  • Investigational Site Number 840003
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 840010
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 840006
    Saint Louis, Missouri 63110, United States
  • Investigational Site Number 840013
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number 840022
    Bozeman, Montana 59718, United States
  • Investigational Site Number 840025
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840008
    Papillion, Nebraska 27103, United States
  • Investigational Site Number 840018
    Princeton, New Jersey 08540, United States
  • Investigational Site Number 840004
    Winston-Salem, North Carolina 27157-1071, United States
  • Investigational Site Number 840023
    Sylvania, Ohio 43560, United States
  • Investigational Site Number 840045
    Oklahoma City, Oklahoma 73120, United States
  • Investigational Site Number 840001
    Lake Oswego, Oregon 97035, United States
  • Investigational Site Number 840012
    Medford, Oregon 97504, United States
  • Investigational Site Number 840016
    Portland, Oregon 97209, United States
  • Investigational Site Number 840040
    Hershey, Pennsylvania 17033, United States
  • Investigational Site Number 840037
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 840009
    Upland, Pennsylvania 19013, United States
  • Investigational Site Number 840027
    Charleston, South Carolina 29407, United States
  • Investigational Site Number 840030
    El Paso, Texas 79902, United States
  • Investigational Site Number 840050
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840052
    South Burlington, Vermont 05403, United States
  • Investigational Site Number 840049
    Richmond, Virginia 23229, United States
  • Investigational Site Number 840020
    Seattle, Washington 98105, United States
  • Investigational Site Number 840019
    Tacoma, Washington 98415-0299, United States
  • Investigational Site Number 840034
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. doi: 10.1056/NEJMoa1304048. Epub 2013 May 21. PubMed 23688323 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 4 years 8 months after primary completion. A results delay was requested in Dec 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2011
First posted
Mar 11, 2011
Start
Mar 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Dec 5, 2013
Results first posted
Jun 8, 2017
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01312961
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 11, 2011
Start date
Mar 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Jun 8, 2017
Last update
Jun 8, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion